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ABSTRACT
Bayesian Models
for DNA Microarray Data Analysis. (May 2004)
Kyeong Eun Lee, B.A., Kyungpook National University, Korea;
M.A., Seoul National University, Korea
Co–Chairs of Advisory Committee: Dr. Bani K. Mallick
Dr. James A. Calvin
Selection of significant genes via expression patterns is important in a microarray
problem. Owing to small sample size and large number of variables (genes), the
selection process can be unstable. This research proposes a hierarchical Bayesian
model for gene (variable) selection. We employ latent variables in a regression setting
and use a Bayesian mixture prior to perform the variable selection. Due to the
binary nature of the data, the posterior distributions of the parameters are not in
explicit form, and we need to use a combination of truncated sampling and Markov
Chain Monte Carlo (MCMC) based computation techniques to simulate the posterior
distributions. The Bayesian model is flexible enough to identify the significant genes
as well as to perform future predictions. The method is applied to cancer classification
via cDNA microarrays. In particular, the genes BRCA1 and BRCA2 are associated
with a hereditary disposition to breast cancer, and the method is used to identify the
set of significant genes to classify BRCA1 and others.
Microarray data can also be applied to survival models. We address the issue
of how to reduce the dimension in building model by selecting significant genes as
well as assessing the estimated survival curves. Additionally, we consider the well-
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known Weibull regression and semiparametric proportional hazards (PH) models for
survival analysis. With microarray data, we need to consider the case where the
number of covariates p exceeds the number of samples n. Specifically, for a given
vector of response values, which are times to event (death or censored times) and p
gene expressions (covariates), we address the issue of how to reduce the dimension by
selecting the responsible genes, which are controlling the survival time. This approach
enables us to estimate the survival curve when n << p. In our approach, rather than
fixing the number of selected genes, we will assign a prior distribution to this number.
The approach creates additional flexibility by allowing the imposition of constraints,
such as bounding the dimension via a prior, which in effect works as a penalty. To
implement our methodology, we use a Markov Chain Monte Carlo (MCMC) method.
We demonstrate the use of the methodology with (a) diffuse large B–cell lymphoma
(DLBCL) complementary DNA (cDNA) data and (b) Breast Carcinoma data.
Lastly, we propose a mixture of Dirichlet process models using discrete wavelet
transform for a curve clustering. In order to characterize these time–course gene
expresssions, we consider them as trajectory functions of time and gene–specific pa-
rameters and obtain their wavelet coefficients by a discrete wavelet transform. We
then build cluster curves using a mixture of Dirichlet process priors.
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1CHAPTER I
INTRODUCTION
1.1. Background: cDNA Microarray
After the invention of the Southern blot, a method for searching for a specific DNA
molecule which introduced a one to one correspondence between clones and hybridiza-
tion signals, the use of non-porous solid supports and development of methods for
high-density spatial synthesis of oligonucleotides opened up the world of DNA mi-
croarray technologies (Lander, 1999) which can provide expression measurements for
thousands of genes at once (Duggan, 1999; Schena et al., 1995). Two main types of
microarray technologies are cDNA microarray and high density oligonucleotide array.
cDNA micoarray experimental procedures can be summarized as follows (Freind
and Stoughton, 2002) :
1. Construct a microarray, containing a single-stranded DNA representing thou-
sands of different genes. Each gene is assigned to a specific spot on a microarray
which has thousands to millions of copies of a DNA strand.
2. Obtain mRNAs from two samples, one reference cell and one test cell.
3. Reverse transcribe unstable mRNA molecules into stable cDNAs and label with
fluorescent dyes, red to cDNAs from the test samples and green to cDNAs from
the reference samples.
4. Apply the labeled cDNA mixture solution to the microarray where it undergoes
competitive binding.
The format and style of this dissertation follows that of Biometrics.
2Fig. 1. cDNA Microarray Schema (Duggan et al., 1999)
5. Using a scanner and a computer, obtain the ratio of the intensities of the red
to green signals at each spot though image analysis.
More details on cDNA microarray are in Nguyen et al. (2002). Figure 1 provides
a schematic overview of a cDNA microarray experiment.
31.2. Outline of Dissertation
Microarray problems can be classified as unsupervised, when only the expression
data are available, and supervised, when a response measurement is available for
each sample. In unsupervised problems the goal is mainly to identify distinct sets
of genes with similar expressions, suggesting that they may be biologically related.
Supervised and unsupervised problems also focus on finding sets of genes that, for
example, relate to different kind of diseases, so that future tissue samples can be
correctly classified. Traditional statistical methods for clustering and classification
have been extensively applied to microarray data, see Eisen et al. (1998), Alizadeh
et al. (2000) for clustering and Golub et al. (1999) and Hedenkalk et al. (2001) for
classification. In the supervised case, a Bayesian approach to dimension reduction
with a probit model has been applied byWest et al. (2000) where rather than selecting
actual genes, the singular-value decomposition is applied to the design matrix to
reduce the dimension of the problem. In Chapter II, we mainly want to identify
(select) important genes which are significantly more influential than the others for
the classification process.
Often, the number of selected genes could be as large as 500 genes or even 2000
genes (Khan et al., 1998; Alon et al., 1999). Even in the studies which obtained
relatively smaller numbers of genes, the numbers also to 50 to 100 (Golub et al.,
1999; Khan et al., 2001). The main problem is that there is a very large set of genes
and typically a small number of microarrays (sample points). So, selecting a large
number genes is usually not advisable due to this small sample size as it can create
an unreliable selection process. Dudoit et al. (2000) proposed a method for the
identification of singly differentially expressed genes, considering a univariate testing
problem for each gene and then corrected for multiple testing using adjusted p-values.
4Tusher et al. (2001) created a Significance Analysis of Microarray (SAM) techinique,
that assigns a score to each gene on the basis of change in gene expression relative to
the standard deviation of repeated measurements. For genes with scores greater than
an adjustable threshold, SAM uses permutations of the repeated measurements to
estimate the percentage of genes identified by chance. Hastie et al. (2000) suggested
gene shaving, a new class of clustering methods which tries to identify subsets of genes
with coherent expression patterns and large variation across conditions. Kim et al.
(2001) suggested a feature selection technique, by fixing the dimension of the selected
genes and using a criterion based method to get the best subset of that dimension.
We suggest a model based approach to this variable selection problem. Rather
than fixing the dimension (the number of selected genes of the problem), we assign
a prior distribution over it. This creates additional flexibility as well as the ability
to impose a constraint by limiting the dimension. So, the prior works as a penalty
to create this constraint. We use a Markov Chain Monte Carlo (MCMC) (Gilks et
al., 1996) based stochastic search algorithm to identify the important genes. Though
the model space is very large, as with p genes (say p=3000) we have 2p models,
and exhaustive computation over this model space is not possible. MCMC based
stochastic search algorithms, which are less greedy and more efficient than most of
the other alternatives, are successfully implemented to identify significant genes. We
consider the model for binary events only, but the extension to multi-category data
is straightforward.
In Chapter III, we consider a situation when survival times of (for example)
cancer patients are of interest. In this setting, it is of interest to identify significant
genes that might control the survival time of the patients. We also want to estimate
the patient survival probabilities controlling for other covariates such as levels of
clinical risk. For example, through gene expression profiling, Alizadel et al. (2000)
5identified two distinct molecular subtypes of diffuse large B-cell lymphoma (DLBCL).
Estimates of patient survival probabilities for the two groups were then compared
using a Kaplan-Meier survival curve.
We suggest a gene selection technique using a Bayesian model based variable
selection approach. Typical Bayesian variable selection methods are based on the
assumptions of Gaussian distributions for the likelihood and use of conjugate mixture
priors to obtain marginal distributions (George and McCulloch, 1993). We extend
our models to the survival data context where the responses are time to event. We
address the issue of how to select the significant genes as well as assess the survival
curves using the Weibull regression or proportional hazards model (PH) where the
sample size is much smaller than the number of variables (genes).
Current techniques used for variable selection in survival models include asymp-
totic procedures based on score tests and other approximate chi-square procedures.
These asymptotic methods may not be valid here because n is much smaller than
p. The literature on Bayesian variable selection for survival models is still sparse.
Raftery, Madigan and Volinsky (1995) had used the approximate BIC criterion for
variable selection. Ibrahim and Chen (2000) advocate a predictive approach which
is efficient with small number of predictors (p is small). As our model space is huge
(2p) we need to construct an efficient search procedure.
We generalize the Gaussian mixture prior approach in this non-Gaussian model-
ing framework. For non-Gaussian data it is well known that conjugate priors do not
exist for regression coefficients. The computations are then potentially much harder,
particularly when sampling from a large model space.
We exploit the use of a random residual component within the model. The use
of a residual component is consistent with the belief that there may be unexplained
sources of variation in the data, perhaps, due to explanatory variables that were not
6recorded in the original study. By adopting a Gaussian residual effect many of the
conditional distributions for the model parameters will be of standard form which
greatly aids in computation.
In Chapter IV, we propose a new model–based approach for curve clustering.
When gene expressions are observed by time, one main concern is now to cluster the
gene expresson patterns over time. In this setting, clustering methods can be divided
into two categories: non–model–based methods and model–based methods. In the
non-model-based methods, such as hierarchical clustering (Eisen et al.,1998), cluster-
ing using correlation (Chu et al.,1999) and self-organising maps (Tamayo et al.,1999),
the time dependency of the gene expression data is not considered, although time is
a possible main factor in the level of gene expression. Model–based clustering meth-
ods are usually based on a finite mixture distribution, especially in the multivariate
normal distribution (Yeung et al, 2001), where the number of clusters is determined
by a model–choice criterion. A mixture–effects model with B–splines using an EM
algorithm (Luan et al., 2003) and hidden markov models (Schliep et al., 2003) are
examples of model–based methods.
We are motivated by Wakefield et al. (2003) who modelled the trajectory as
a function of time and gene specific parameters, and clustered these curves using a
reversible jump MCMC. Wakefield et al. (2003) used a first-order random walk model
for gene-based parameters in a sporulation data (Chu et al.,1999) and a mixture of
periodic function model for the cell–cycle data (Spellman et al.,1998)).
We propose a mixture of Dirichlet processes model using a discrete Wavelet
transform for curve clustering as a fully Bayesian approach. Each iteration of the
MCMC algorithm generates the cluster structure of these coefficients as a by-product
(Escobar et al.,1998). We use a marginal posterior mode of their cluster memberships.
7CHAPTER II
GENE SELECTION: A BAYESIAN VARIABLE SELECTION APPROACH*
2.1. Introduction
In this Chapter we will suggest a model based approach to this variable selection
problem. Rather than fixing the dimension (the number of selected genes in the
problem), we will assign it a prior distribution. This creates additional flexibility,
as well as the ability to impose a constraint by limiting the dimension through the
support of the prior. So, the prior works as a penalty to create this constraint. We
will use a Markov Chain Monte Carlo (MCMC) (Gilks et al., 1996) based stochastic
search algorithm to identify the important genes. Though the model space is very
large, as with p genes (say p=3000) we have 2p models, and exhaustive computation
over this model space is not possible. MCMC based stochastic search algorithms,
which are less greedy and more efficient than most of the other alternatives, are
successfully implemented to identify significant genes. We have considered the model
for binary events only, but the extension to multi-category data is straightforward.
We will consider a data set from Hedenfalk et al. (2001) comparing the expression
profiles of hereditary breast cancers. We want to identify the useful genes that can
discriminate between BRCA1 and BRCA2 or sporadic breast cancers. The idea is
to identify a small number of genes (by penalizing the dimension) that have the
greatest discriminating power, thereby allowing researchers to quickly focus on the
most promising candidates for diagnostics and therapeutics.
*Reprinted with permission from ”Gene Selection: a Bayesian Variable Selection
Approach” by Kyeong Eun Lee, Naijun Sha, Edward R. Dougherty, Marina Vannucci
and Bani K. Mallick, 2003. Bioinformatics, Vol. 19, 90–97. 2003 by Oxford University
Press.
82.2. Model for Gene Selection
We have binary responses,Y, where Yi=1 indicates the tumor sample i is class1 and
Yi = 0 indicates it is class2, for i = 1, · · ·n. For each sample, we have a measurement
of the expression levels for all the genes, so Xij is the measurement of the expression
level of the jth gene for the ith sample where j = 1, · · · p.
Response Gene 1 Gene 2 · · · Gene p
Y1 X11 X12 · · · X1p
Y2 X21 X22 · · · X2p
...
...
...
. . .
...
Yn Xn1 Xn2 · · · Xnp

We assume that Yi have the independent binary distributions so that Yi = 1
with probability pi, and it is independent of other Yj, j 6= i. Then we relate the gene
expression level with the response using a probit regression model which yields
Pr(Yi = 1|β) = Φ(X ′iβ)
where Xi is the ith row of the matrix X (vector of gene expression levels of the
ith sample), β is the vector of regression parameters (βj is the regression parameter
corresponding to the jth gene) and Φ is the cumulative normal distribution function.
Albert and Chib (1994) introduced n independent latent variables Z1, · · · , Zn
into the binary response regression, where Zi ∼ N(X ′iβ, 1)
Yi =
 1 Zi > 0
0 Zi ≤ 0
.
The latent variable has a linear model form as Zi = X
′
iβ+ ²i where ²i ∼ N(0, 1).
We now define γ to be the p × 1 vector of indicator variables with ith element
9γi such that γi = 0 if βi = 0 (the gene is not selected) and γi = 1 if βi 6= 0 (the
gene is selected). Given γ, βγ consists of all nonzero elements of β, and let Xγ be the
columns of X corresponding to those elements of γ that are equal to 1. To complete
the hierarchical model we need make the following prior assumptions:
(1) Given γ, the prior for βγ|γ is βγ ∼ N(0, c(X ′γXγ)−1) where c is a positive
scale factor specified by the user. After extensive testing, Smith and Kohn (1996)
suggested to choose c between 10 to 100 for linear model problems. We will fix it to a
large value, c = 100, so that the prior of βγ, given γ, contains very little information
about βγ compared to the likelihood.
(2) The γi are assumed a priori to be a independent with Pr(γi = 1) = pii, 0 ≤
pii ≤ 1, for i = 1, · · · , p. Now the value of pii will be chosen to be small which will
restrict the number of genes in the model. Here if we have prior knowledge that
some genes are more important than others, we can implement computation easily
by assigning larger or smaller value of pi in the scale of importance 0 to 1. This prior
is more useful when we will try to model a priori the interaction among the genes.
The choice of a small value of pi will indirectly restrain the number of selected genes
in the model.
2.3. Computation
Due to the binary nature of the data we cannot obtain the posterior distribution in
explicit form. So we use a MCMC method (Gilks et al., 1996), specifically Gibbs
sampling (Gelfand and Smith, 1990), to generate the posterior distributions of pa-
rameters.
Our unknowns are (Z, β, γ). To implement Gibbs sampling we need to simulate
from the complete conditional distributions. Rather than drawing from the complete
10
conditional distributions we modify the algorithm and draw γ from the marginal
distribution (integrating β) which speeds up the computation. It can be shown that
this modified Gibbs sampler still leaves the target posterior distribution invariant. So
our computation is:
(i) Draw from γ|Z, the marginalized conditional distribution obtained after in-
tegrating out β (this conditionally independent of Y ). Now,
p(Z|γ) ∝
∫
β
p(Z|βγ)p(βγ|γ)dβγ
∝ exp[−1/2(Z ′Z − c
1 + c
Z ′Xγ(X ′γXγ)
−1
X ′γZ)].
The proof is a simple application of Bayesian linear model theory (Lindley and Smith,
1972; Denison et al., 2002) and provided in the appendix.
The conditional distribution of γ|Z is
p(γ|Z) ∝ p(Z|γ)p(γ)
∝ exp[−1/2(Z ′Z − c
1 + c
Z ′Xγ(X ′γXγ)
−1
X ′γZ)]Π
p
i=1pii
γi(1− pii)1−γi
Rather than sampling γ as a vector, it is better to draw component wise of the
vector, γ, from p(γi|Z, γj 6=i) which is
p(γi|Z, γj 6=i) ∝ p(Z|γ)p(γi)
∝ exp[−1/2(Z ′Z − c
1 + c
Z ′Xγ(X ′γXγ)
−1
X ′γZ)]pii
γi(1− pii)1−γi .
(ii) Draw from βγ|γ, Z, (which is conditionally independent of Y ), p(β|γ, Z) ∼
N(VγX
′
γZγ, Vγ) where Vγ =
c
1+c
(X ′γXγ)
−1 and the index vector γ means all the ele-
11
ments only corresponding to γi = 1, i = 1, · · · , n.
(iii) The full conditional distribution of Zi is as follows:
Zi|β, Yi = 1 ∝ N(X ′iβ, 1) truncated at the left by 0
Zi|β, Yi = 0 ∝ N(X ′iβ, 1) truncated at the right by 0
The distribution of Z is a truncated normal and can be generated using Robert’s
(Robert, 1995) optimal exponential accept-reject algorithm.
After suitable burn-in period (usually 10,000) we obtained the MCMC samples
at the t-th iteration as {β(t), Z(t), γ(t), t = 1, · · · ,m}. We can use these samples from
the posterior distributions for posterior inference and prediction.
The Algorithm
Start with initial values [γ(0), Z(0), β(0)]
At the tth iteration
(i) Draw γ(t) from p(γ|Z(t−1)).
(ii) Draw Z(t) from p(Z|β(t−1), γ(t)).
(iii) Draw β(t) from p(β|Z(t), γ(t)).
(iv) Let t← t+ 1.
Continue required number of iterations.
Stop
For decision making we can calculate the relative number of times each gene
appeared in the MCMC sample (number of time the corresponding γ is 1). This will
give us an estimate of the posterior probability of inclusion of that gene and tell us
the relative importance of the gene for classification purposes.
We can also obtain the predictive classification of a new observation Ynew condi-
12
tion on the expression levels as
P (Ynew = 1|X) =
∫
Z
∫
β
p(Ynew = 1|X,Z, β)p(z, β|Y )dZdβ (2.1)
and the Monte-Carlo estimate of this probability will be
Pˆ (Ynew = 1|X) = 1
m
m∑
t=1
p(Ynew = 1|X,Z(t), β(t), γ(t))
and can be easily evaluated using normal cumulative distribution function.
2.4. Application of Gene Selection to Hereditary Breast Cancer Data
We apply the proposed strategy for discovering significant genes to a published data
set (Hedenfalk et al.,2001) consisting of patients carrying mutations in predispoing
genes, BRCA1, and patients not expected to carry a hereditary predisposing muta-
tion. Pathological and genetic differences appear to imply different but overlapping
functions for BRCA1 and BRCA2. In Hedenfalk et al. (2001), cDNA microarrays
were used in conjuction with classification algorithms to show the feasiblity of using
differences in global gene expression profiles to separate BRCA1 and BRCA2 type.
They examined 22 breast tumor samples from 21 breast cancer patients. All patients
except one were women; fifteen of the women had hereditary breast cancer, seven tu-
mors with BRCA1 and eight tumors with BRCA2. In the analysis, 3226 genes were
used for each breast tumor sample. We used our method to classify BRCA1 versus
non–BRCA1 (BRCA2 and sporadic) samples.
We used two sample t–statistics to identify the starting value for γ by identifying,
say, the five most significant genes. We then ran the MCMC sampler, in particular,
the Gibbs sampling approach fixing pii = .005 for all i = 1 · · · p. The chain moved
quite frequently and we used 50,000 iterations after a 10,000 iteration burn in period.
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In Table I, we present the strongly significant genes with the largest frequencies.
We note that the three leading genes in Table I appear among the six strongest
genes in an analogous list in Kim et al. (2002). This has occurred even though the
rating in the latter paper is based upon the ability of a gene to contribute to a linear
classifier, which is quite different than the criterion here. One of the strongest selected
genes is keratin 8 (KRT8) is a member of the cytokeratin family of genes. Cytokeratins
are frequently used to identify breast cancer metastases by immunohistochemistry,
and keratin 8 abundance has been shown to correlate well with node-positive disease
(Brotherick et al., 1998). The gene TOB1 is the first in Table I, and appeared fifth in
Kim et al. (2002). It interacts with the oncogene receptor ERBB2, and is found to
be more highly expressed in BRCA2 and sporadic cancers, which are likewise more
likely to harbor ERBB2 (Matsuda et al., 1996). We note that the gene for the receptor
was not on the arrays, so that the gene-selection algorithm was blinded to its input.
Lastly, the second gene in Table I, appears as the sixth gene in the list of Kim et al.
(2002).
Heat maps have become popular in the microarray literature, as graphical repre-
sentations of the primary data where each point is associated with a color that reflects
its value. Increasingly positive values are represented with reds of increasing inten-
sity, overexpressed, and increasing negative values with greens of increasing intensity,
underexpressed. A heat map of the identified genes is Figure 2. From this Figure 2,
we are able to detect some patterns which indicates existence of different classes.
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Table I. Strongly Significant Genes Found for Classifying BRCA1 versus Non BRCA1
Freq. Image Clone ID Gene Description
8.4 823940 ”transducer of ERBB2, 1”
7.8 26184 ”phosphofructokinase, platelet”
7.5 840702 SELENOPHOSPHATE SYNTHETASE
; Human selenium donor protein
7.1 897781 keratin 8
7.1 376516 cell division cycle 4-like
6.9 47542 small nuclear ribonucleoprotein D1 polypeptide (16kD)
6.6 366647 butyrate response factor 1 (EGF-response factor 1)
6.6 293104 phytanoyl-CoA hydroxylase (Refsum disease)
6.2 28012 O-linked N-acetylglucosamine (GlcNAc) transferase
6.1 212198 ”tumor protein p53-binding protein, 2”
5.9 247818 ESTs
5.5 26082 very low density lipoprotein receptor
5.4 667598 PC4 and SFRS1 interacting protein 1
5.2 30093 RAN binding protein 1
5.1 73531 nitrogen fixation cluster-like
5 950682 ”phosphofructokinase, platelet”
5 47681 ”splicing factor, arginine/serine-rich
(transformer 2 Drosophila homolog)”
4.9 46019 minichromosome maintenance deficient (S. cerevisiae) 7
4.9 307843 ESTs
4.8 548957 ”general transcription factor II, i, pseudogene 1”
4.7 788721 KIAA0090 protein
4.7 843076 signal transducing adaptor molecule
(SH3 domain and ITAM motif)
4.7 204897 ”phospholipase C, gamma 2 (phosphatidylinositol-specific)”
4.7 812227 ”solute carrier family 9, isoform 1”
4.6 566887 heterochromatin-like protein 1
4.6 563598 ”gamma-aminobutyric acid (GABA) A receptor, pi”
4.5 324210 sigma receptor (SR31747 binding protein 1)
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Fig. 2. Breat Cancer Data: Heat Map
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We can check the model adequacy in two ways. (i) Cross validation: we use the
cross-validation predictive density (Wilks et al., 1996),
fˆ(yi|Y−i) = 1
1
M
M∑
m=1
1
f(yi|Y−i,θ∗m)
=
1
1
M
M∑
m=1
1
f(yi|θ∗m)
,
where θ∗m is the mth MCMC sample, and predict Y = 1 for that point if fˆ(yi =
1|Y−i) > .5. The second equality holds due to the conditional independency of yi
given θ.
(ii) Deviance: Deviance calculation is one of many criterion based methods that
measures goodness of fit (McCullagh and Nelder, 1983). Lower deviance means better
fit. We have calculated the probabilities and the deviance measures for different
models in Table II which shows the adequacy of the models.
Model1: Using all genes in Table I
Model2: Using genes with frequencies more than 5%
Model3 : Using genes with frequencies more than 6%
Model4 : Using genes with frequencies more than 7%
We compared our cross validation results with other popular classification algo-
rithms including feed forward neural networks, k-nearest neighbors, support vector
machines (SVM) result in Table III. All other methods in Table III have used 51
genes (which we think is too many with respect to a sample size of 22) which may
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produce instability in the classification process. Our procedure has used far fewer
genes though the results are competitive to these other methods.
All the analyses we have presented are mainly marginal analyses of genes. The
best model (with respect to minimum deviance criterion) we picked from all the
samples is a 4 variable model and presented in Table IV.
Table II. Cross Validation of Breast Cancer Data
Model 1 Model 2 Model 3 Model 4
Y Pr(Y=1) Pr(Y=1) Pr(Y=1) Pr(Y=1)
1 1 1 0.9993 0.9998
1 1 1 1 0.9969
1 1 1 0.9999 1
1 1 1 0.9999 0.8605
1 1 1 0.9999 0.7766
1 1 1 0.9998 1
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0.0002
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0.0002
0 0 0 0.0018 0.0867
0 0 0 0.0005 0.007
0 0 0 0 0
0 0 0 0 0.2864
1 1 1 1 1
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
Deviance 1.2683e− 12 3.1464e− 7 0.0071 1.6843
Number of misclassifications 0 0 0 1
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Table III. Cross Validation Errors of Different Models for Breast Cancer Data
Model Cross-Validation Error∗
1 Feed-forward Neural Networks 0
(3 hidden neurons, 1 hidden layer) (An average of 1.5 misclassifications)
2 Gaussian Kernel 1
3 Epanechnikov Kernel 1
4 Moving Window Kernel 2
5 Probabilistic Neural Network (r=0.01) 3
6 kNN(k=1) 4
7 SVM Linear 4
8 Perceptron 5
9 SVM Nonlinear 6
∗: Number of Misclassified Samples Feature Selection: 51 Features used in the paper
’Gene-Expression Profiles in hereditary Breast Cancer’, Vol 344, NJE
2.4.1. Sensitivity Analysis
We have checked the sensitivity of our analysis to the measurement of expression
levels (as they are always subject to measurement errors) by adding Gaussian noises
to the expression values. We reanalyzed the data contaminated by different levels of
Gaussian noise to obtain the newly selected genes and have reproduced them in Table
V.
It is clear from the table that our analysis is stable as it is selecting almost similar
genes under different noise levels over the expression values. Among the seven leading
genes in Table I , the following appear across all noise conditions in Table V : Keratin
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Table IV. The Best Model in the Breast Cancer Data
Image Clone ID Gene Description
HV5H10 ”transducer of ERBB2, 1”
HV16C12 pyruvate dehydrogenase (lipoamide) beta
HV33F6 ”protein phosphatase 3 (formerly 2B), regulatory subunit B”
HV44D9 hypothetical protein PRO0823
Deviance 0.0071
8, phosphofructokinase platelet, Selenophosphate synthetase, and butyrate response
factor 1. TOB1 is only omitted at the highest noise level.
To check the prior sensitivity we have rerun our algorithm for several choices of
c between 10 and 100 and the results are not that sensitive towards the choice of c.
We suggest to fix a large value of c (say 100) as it is almost a non-informative prior.
The number of genes selected are very sensitive towards the choice of pi. On average
the number of genes selected will be m×pi where m is the total number of genes. For
our case m = 3226 and sample size is only 23. With this small sample size we don’t
want to select too many genes (not more than 23) and we can restrain the number of
selected genes by choosing pi to be small. For example if we want to keep the number
of selected genes around 23 the choice of pi should be 0.007. This way the Bayesian
method is successful to penalize the number of selected genes through the help of the
prior specifications. We reanalyzed the data for several choices of pi from 0.001 to 0.1
which selects different number of genes in different cases but the identification of the
frequency arising genes remained same.
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Table V. Breast Cancer Data: Sensitivity Analysis
Error ∼ N(0, 0.12) Error ∼ N(0, 0.22) Error ∼ N(0, 0.52)
Freq. Image Clone ID Freq. Image Clone ID Freq. Image Clone ID
10.5 840702∗ 10.5 26184∗ 12.7 840702∗
9.5 897781∗ 10.1 840702∗ 10.4 26184∗
8.6 247818∗ 9.6 897781∗ 9.0 293104∗
8.3 26184∗ 7.6 566887 9.0 897781∗
7.7 212198∗ 7.6 293104∗ 8.0 247818∗
7.5 307843∗ 7.3 46019∗ 7.8 307843∗
7.4 47681∗ 7.3 212198∗ 7.8 566887∗
6.8 293104∗ 6.9 247818∗ 7.4 548957∗
6.3 823940∗ 6.8 564803 7.1 46019∗
5.7 566887∗ 6.3 788721∗ 7.1 810899
5.7 28012∗ 6.0 366647∗ 6.6 46182
5.6 376516∗ 5.9 307843∗ 6.5 47681∗
5.5 46019∗ 5.9 73531∗ 6.4 366647∗
5.4 548957∗ 5.8 825478∗ 6.4 28012∗
5.3 26082∗ 5.8 28012∗ 6.3 843076∗
5.3 46182 5.4 376516∗ 6.0 26082∗
5.3 30093∗ 5.3 204897∗ 5.9 788721∗
5.1 366647∗ 5.2 26082∗ 5.8 667598∗
5.0 248531 5.2 248531 5.7 212198∗
4.9 246524 5.2 47681∗ 5.6 73531∗
4.9 204897∗ 5.1 667598∗ 5.5 30093∗
4.7 139540 5.0 810899∗ 5.3 825478∗
4.7 47542∗ 5.0 823940∗ 5.3 246524
4.4 32790 4.8 843076∗ 5.1 564803
4.4 134748 4.8 46182 5.0 248531
4.3 810899∗ 4.7 246524 4.9 897646
4.2 667598∗ 4.7 324210∗ 4.8 950682
∗: Selected genes which were already in the original analysis.
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2.5. Application to Leukemia Data
Now we apply our method to a larger data set with a test set where we can per-
form our prediction validation. The leukemia data set was described by Golub et al.
(1999). Bone marrow or peripheral blood samples were taken from 72 patients with
either myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Following
the experimental setup of the original paper, the data were split into a training set
consisting of 38 samples of which 27 are ALL and 11 are AML, and a test set of 34
samples, 20 ALL and 14 AML. The dataset contains expression levels for 7129 human
genes produced by Affymetrix high-density oligonucleotide microarrays. The scores
in the dataset represent the intensity of gene expression after being rescaled to make
overall intensities. Golub et al. (1999) used a predictor trained using a weighted vot-
ing scheme on the training samples, and classifyed correctly on all samples for which
a prediction is made, 29 of the 34, declining to predict for five samples. We performed
our anlaysis with the same choices of the hyper parameters as in the first example
and report here our resluts. In Table VI, we provide the genes which appeared more
frequently in our posterior samples. There are several genes, including the top one,
that also belong to the set of 50 genes used by Golub et al. (these genes are reported
with asterisks in Table VI). We considered five models based on marginal frequencies
as follows:
Model1 : Using genes with frequencies more than 115
Model2 : Using genes with frequencies more than 125
Model3 : Using genes with frequencies more than 150
Model4 : Using genes with frequencies more than 200
Model5 : Using genes with frequencies more than 250
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We have calculated the probabilities and the deviance measures for different
models in Table VII which shows the adequacy of the models. We used the genes
that appeared more than 250 (appeared to be the top 5 genes) to perform predictions
on the test data. The prediction results are reported in Table VIII. Only one obser-
vation is misclassified (the observation number 29). These results appear to improve
predictions made by Golub et al. (1999) and use only 5 genes (Model5) rather than
50. Figure 3 shows the heat map of the 27 genes (Model1) identified by our methods
which differentiate two different classes, ALL and AML.
2.6. Discussion
We have proposed a Bayesian model to identify important genes using expression level
data, by forming the problem as a variable selection problem for binary data. We
have used a hierarchical probit model and MCMC based stochastic search techniques
to obtain the posterior distributions. We have proposed one based on Gibbs sampling.
Though ideally the Metropolis–Hastings algorithm should be faster, it has a tendency
to stick a region due to the high dimensionality of the problem. We have mainly used
the Gibbs algorithm in this paper but in future we will investigate the more adaptive
MH algorithm (or a mixture of two) to speed up our computation.
Here we have fixed the pi value but we can extend our model assuming pi is an
unknown model parameter. Assigning a conjugate beta distribution prior on pi, the
extension is straightforward.
We have assumed the genes are independent but in our framework we can very
easily extend it for dependent cases. For example: consider if the event where the
ith gene expression increases the chance that jth gene will be expressed. In our
framework we can account for the dependence through the prior distribution of γ.
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Rather than assuming the γi are independently distributed we can use a Markov
model whose transition matrices will be defined as p(γj = 1|γi = 1). This type of
problem will be handled in future research.
In this paper we have considered binary data. Extension to more than two
categories can be found in Albert and Chib (1993) and development of a variable
selection model in that setup is in Sha (2002).
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Table VI. Leukemia Data: Strongly Significant Genes Found for Classification
Freq. ID Gene Description
77.2 1882 CST3 Cystatin C (amyloid angiopathy and cerebral hemorrhage)*
48.5 760 CYSTATIN A
28.3 2288 DF D component of complement (adipsin)*
27.8 4847 Zyxin*
26.8 1144 ”SPTAN1 Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)”
24.2 1120 SNRPN Small nuclear ribonucleoprotein polypeptide N
21.1 4535 RETINOBLASTOMA BINDING PROTEIN P48
19.8 6218 ”ELA2 Elastatse 2, neutrophil”
19.5 6200 Interleukin 8 (IL8) gene *
19.5 1834 CD33 CD33 antigen (differentiation antigen)*
18.8 1630 Inducible protein mRNA*
17.9 5772 C-myb gene extracted from Human (c-myb) gene*
16.9 1745 LYN V-yes-1 Yamaguchi sarcoma viral related oncogene homolog*
16.7 804 Macmarcks
16.1 2354 CCND3 Cyclin D3 *
14.9 3252 ”GLUTATHIONE S-TRANSFERASE, MICROSOMAL”
13.5 6201 INTERLEUKIN-8 PRECURSOR*
13.5 1685 Terminal transferase mRNA
13.1 6041 APLP2 Amyloid beta (A4) precursor-like protein 2
13.1 1779 MPO Myeloperoxidase
12.7 6855 TCF3 Transcription factor 3
12.6 173 ”PRKCD Protein kinase C, delta”
12 2642 MB-1 gene*
12 1829 PPGB Protective protein for beta-galactosidase
11.9 4107 PLECKSTRIN
11.8 697 ”KIAA0235 gene, partial cds”
11.7 229 KIAA0102 gene
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Fig. 3. Leukemia Data: Heat Map
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Table VII. Crossvalidated Classification Probabilities and Deviance for the Leukemia
Data
Y Φ(X1βˆ1) Φ(X2βˆ2) Φ(X3βˆ3) Φ(X4βˆ4) Φ(X5βˆ5)
1 1 1 1 1 1
1 1 0.9998 0.9993 0.9982 0.9813
1 1 1 1 1 1
1 1 1 1 0.9998 1
1 1 1 0.9998 0.9985 0.9938
1 1 1 0.9999 0.9996 1
1 1 0.9999 0.9996 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 0.9958 0.9933
1 1 1 1 1 1
1 1 1 0.9991 0.9993 0.9999
1 1 1 1 0.9999 0.9999
1 1 1 0.9988 0.994 0.9974
1 1 1 1 0.9994 0.9969
1 1 1 1 0.9997 0.9985
1 1 0.9999 0.9959 0.9909 0.9879
1 1 1 0.9999 1 1
1 1 1 1 0.9987 1
1 1 1 1 1 0.9986
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 0.9994 1 1
1 1 1 1 1 1
1 1 1 1 0.9999 1
1 1 1 1 1 1
1 1 1 1 1 1
0 0 0 0.0037 0.0158 0.0083
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0.0011
0 0 0.0001 0.0005 0.0004 0
0 0 0 0 0 0
0 0 0 0 0 0.0001
0 0 0.0001 0 0 0.0174
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0.0004 0.0003
Deviance 3.53E-08 0.0014 0.025 0.0863 0.1605
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Table VIII. Leukemia Data: Prediction on the Test Set Using Genes with Frequencies
Higher than 250
Y Φˆ(Xtestβˆ) Y Φˆ(Xtestβˆ)
1 1.0000 1 0.2503
1 1.0000 1 1.0000
1 1.0000 1 1.0000
1 0.9972 1 0.9999
1 1.0000 1 1.0000
1 1.0000 1 1.0000
1 1.0000
1 1.0000
1 1.0000
1 1.0000
1 1.0000
0 0.0000
0 0.0000
0 0.0000
0 0.0000
0 0.0000
1 0.9963
1 1.0000
0 0.0000
0 0.0000
1 1.0000
0 0.0000
0 0.1143
0 0.0000
0 0.0000
0 0.0000
0 0.0000
0 0.0612
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CHAPTER III
BAYESIAN METHODS FOR VARIABLE SELECTION IN THE SURVIVAL
MODEL FOR APPLICATION TO DNA MICROARRAY DATA
3.1. Introduction
In this chapter, we suggest a variable selection technique for survival models using a
Bayesian model–based variable selection approach. Typical Bayesian variable selec-
tion methods are based on the assumptions of Gaussian distributions for the likelihood
and use of conjugate mixture priors to obtain marginal distributions (George and Mc-
Culloch, 1993). We will extend such models to the survival data context where the
responses are time to event. We will address the issue of how to select the significant
predictors as well as assess the survival curves using the Weibull regression or propor-
tional hazards model (PH) where the sample size is much smaller than the number
of predictors (genes).
Current techniques used for variable selection in survival models include asymp-
totic procedures based on score tests and other approximate chi-square procedures.
These asymptotic methods may not be valid here because n is much smaller than
p. The literature on Bayesian variable selection for survival models is still sparse.
Raftery, Madigan and Volinsky (1995) had used the approximate BIC criterion for
variable selection. Ibrahim and Chen (2000) advocate a predictive approach which is
efficient with a small number of predictors (p is small). As our model space is large
(2p), we need to construct an efficient selection procedure.
We will generalize the Gaussian mixture prior approach to this non-Gaussian
modeling framework. For non-Gaussian data it is well known that conjugate priors do
not exist for the regression coefficients. Computation is then potentially much harder
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particularly when sampling the dimension of the model space. This is due to possibly
strong posterior correlation between the elements of regression parameters such that
adding or removing a variable can result in a large drop in the model likelihood unless
careful update proposals are made to the coefficients to accommodate the change.
The construction of good proposals is not trivial and depends on both the form of
the model and on the data.
In this chapter we exploit the use of a random residual component within the
model. The use of a residual component is consistent with the belief that there may
be unexplained sources of variation in the data, perhaps due to explanatory variables,
that were not recorded in the original study. By adopting a Gaussian residual effect,
many of the conditional distributions for the model parameters will be of standard
form which greatly aids in the computations.
It is quite a new approach to do a variable selection in the survival model when
the sample size is much smaller than the number of variables. Our proposed method
can be particularly useful for the general large p small n situations and not just for
DNA microarray data.
We will consider two cDNA data sets: B-cell lymphoma data set(Alizadeh et al.
2000) and breast carcinoma samples (Sørlie et al. 2001). We want to identify a set
of responsible genes which explain the survival time in each data set.
3.2. Weibull Regression Model
Let Ti be the survival time (observed or censored) for the ith patient and Xijs are the
p+1 covariates associated with it. Usually Xi0 indicates the binary or multi-category
phenotype covariate and other Xijs are p gene expressions from DNA microarray
data, which is continuous in nature.
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
Survival Time
t1
t2
...
tn


Category Gene 1 Gene 2 · · · Gene p
X10 X11 X12 · · · X1p
X20 X21 X22 · · · X2p
...
...
...
. . .
...
Xn0 Xn1 Xn2 · · · Xnp

In this section, we assume a parametric model, say, the Weibull distribution for
the survival time. Suppose we have independently distributed survival time, t =
(t1, · · · , tn)′, which follows the Weibull distribution with a shape parameter α and a
scale parameter γ∗i .
f(t|α, γ∗) =
αγ
∗tα−1 exp(−γ∗tα) for t > 0, α > 0, γ∗ > 0
0 o.w.
It is more convenient to write the model in terms of the reparametrization λ = log(γ∗),
and its corresponding pdf is
f(t|α, λ) = αtα−1 exp(λ− exp(λ)tα)I(t > 0, α > 0),
its hazard function is h(t|α, λ) = α exp(λ)tα−1 and its survival function is S(t|α, λ) =
exp(− exp(λ)tα). The censoring indicator variables are δ = (δ1, · · · , δn)′, where
δi =
 0 if ti is right censored
1 if ti is a death time
.
The likelihood function of λ and α :
L(α,λ|D) =
n∏
i=1
f(yi|α, λi)δiS(yi|α, λi)(1−δi)
= αd exp
{
n∑
i=1
(δiλi + δi(αi) log(yi))−
n∑
i=1
(exp(λi)y
α
i )
}
(3.1)
where D = (n, t, δ).
In order to build up a Weibull regression model and perform the variable selec-
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tion, we developed a hierarchical model introducing the covariate x (gene expression)
through λ as λi = X
′
iβ. As mentioned earlier, with a complicated likelihood as in (1),
it is hard to identify a conjugate mixture prior distribution to perform the variable
selection. We overcome the computational difficulty by including a random residual
component ²i. The model is modified as
λi = X
′
iβ + ²i, where ²i ∼ N(0, σ2).
This introduction of ² enables to generate samples from full conditionals of all other
parameters which is consistent with the belief that there may be unexplained sources
of variation in the data, perhaps departure from the assumption of linearity. Now
we can construct the Gaussian mixture prior for β to perform the variable selection
procedure. Define γ to be an arbitrary p × 1 vector of indicator variables with ith
element γi such that γi = 0 if βi = 0 (the gene is not selected) and γi = 1 if βi 6= 0
(the gene is selected). Given γ, let βγ consist of all nonzero elements of β and let xγ
be the columns of x corresponding to those elements of γ that are equal to 1. To
complete the hierarchical model we need make the prior assumptions:
1. Given γ, the prior for βγ will be βγ ∼ N{0, c(X′γXγ)−1}, where c is a positive
scale factor specified by the user. Smith and Kohn (1996) suggested to choose
c between 10 to 100 for linear model problems. We will fix c = 100, so that the
prior of βγ , given γ, contains little information about βγ .
2. The γi will be assumed to be a priori independent with pr(γi = 1) = pii. The
values of pii will be chosen to be small which will restrict the number of genes
in the model. For example if we have 3000 total number of genes and want to
allow only 15 genes due to small sample size, then we will fix pii ≡ 0.005 to
achieve the purpose. In addition, if we have prior knowledge that some genes
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are more important than others, we can incorporate this easily by assigning
larger values of pi.
So our hierarchical structure of the model for variable selection is as follows:
[Ti|α, λi] ∼Weibull(α, λi)
[λi|β, σ] ∼ Gaussian(xi′β, σ2)
[βi|γi] ∼ Gaussian(0, γicσ2)
[γi] ∼ Bernoulli(pii)
[α] ∼ Gamma(α0, κ0)
[σ2] ∼ InverseGamma
(
a0,
b0
2
)
.
As the posterior distributions of the parameters are not of explicit form, we need
to use Markov Chain Monte Carlo (MCMC) based approaches, specifically Gibbs
sampling and Metropolis algorithms to generate samples from the posterior distribu-
tion. All the conditional distributions required for MCMC are obtained in the next
section.
3.2.1. Conditional Distributions and Posterior Sampling
To perform Gibbs sampling we need to obtain the conditional distributions of the
parameters as follows.
For the convenience, let θ = log(α). The conditional distribution of λ is
p(λ|D, βγ, θ, σ2) ∝ exp
{
θd+
n∑
i=1
(νiλi + νi(e
θ − 1) log(yi))−
n∑
i=1
(eλiye
θ
i )
}
× exp
{
− 1
2σ2
(λ−Xγβγ)′(λ−Xγβγ)
}
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Since λi’s are conditionally independent, it is convenient to draw componentwise.
p(λi|D,λj 6=i,βγ , θ, σ2) ∝ exp
{
θd+ νiλi + νi(e
θ − 1) log(yi)− exp(λi)yeθi
}
× 1
σ
exp
{
− 1
2σ2
(λi −X′γ ,iβγ)2
}
where Xγ ,i is the ith column of Xγ .
The conditional distribution of θ is
p(θ|D,λ, βγ, σ2) ∝ exp
{
θd+
n∑
i=1
(νiλi + νi(e
θ − 1) log(yi))−
n∑
i=1
(eλiye
θ
i )
}
× eθ(α0−1) exp(−κ0eθ)eθ
In order to speed up the computation, we draw γ from the marginal distribu-
tion(integrating β out). Since p(λ,βγ |σ2) = p(λ|βγ, σ2)p(βγ|σ2),
p(λ|βγ, σ2)p(βγ|σ2) ∝
|X ′γXγ|−1/2
(cσ2)qγ/2
1
σn
exp
{
− 1
2σ2
(1 + c−1)β′γ(X
′
γXγ)βγ + λ
′Xγβγ
}
× exp
(
− 1
2σ2
λ′λ
)
= exp
(
−1
2
β′γV
−1
γ βγ + β
′
0V
−1
γ βγ −
1
2
β′0V
−1
γ β0
)
×|X
′
γXγ|−1/2
(cσ2)qγ/2
exp
(
− 1
2σ2
λ′λ
)
where Vγ = σ
2 c
1 + c
(X′γXγ)
−1
and β0 =
c
1 + c
(X′γXγ)
−1X′γλ.
So
p(λ|γ, σ2) ∝
∫
β
p(λ|βγ , σ2)p(βγ |γ, σ2)dβγ
∝
(
1
1 + c
)qγ/2
exp
{
− 1
2σ2
S(γ)
}
where S(γ) = λ′λ− c
1 + c
λ′Xγ(X′γXγ)
−1X′γλ.
Therefore, the marginal distribution of γ is
p(γ|λ, σ2) ∝ p(λ|γ, σ2)p(γ)
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∝ (1 + c)−qγ/2exp
{
− 1
2σ2
S(γ)
} n∏
i=1
pii
γi(1− pii)1−γi .
Now rather than drawing γ as a vector, it is better to draw component wise from
p(γi|λ, γj 6=i) which is
p(γi|λ,γj 6=i, σ2) ∝ p(λ|γ, σ2)p(γi)
∝ (1 + c)−qγ/2 exp
{
− 1
2σ2
S(γ)
}
pii
γi(1− pii)1−γi .
Since
p(γi = 1|λ,γj 6=i, σ2) ∝ pii(1 + c)
−qγi1/2 exp
{
− 1
2σ2
S(γi
1)
}
p(γi = 0|λ,γj 6=i, σ2) ∝ (1− pii)(1 + c)
−qγi0/2 exp
{
− 1
2σ2
S(γi
0))
}
where γi
1 = (γ1, · · · , γi = 1, · · · , γp) and γi0 = (γ1, · · · , γi = 0, · · · , γp),
p(γi = 1|λ, γj 6=i, σ2) = 1
1 +
1− pii
pii
(1 + c)1/2 exp{−1
2
(S(γ0)− S(γ1))}
.
Since p(βγ|λ, σ2) ∝ p(λ|βγ , σ2)p(βγ |σ2),
p(βγ |λ, σ2) ∝ exp{−
1
2
(βγ − β0)′V −1γi (βγ − β0)}.
So the posterior distribution of βγ is
βγ |γ,λ, σ2 ∼MN(VγX′γλ,Vγ).
Similarly the conditional distribution of σ2 is again an inverse-gamma distribu-
tion.
It is clear from the expressions that due to the introduction of ²i, β and σ and
γ are conditionally independent of T and α, hence standard normal linear model
(Lindley and Smith, 1978) results can be exploited to generate from the conditional
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distributions or to marginalize them. We make use of these conditional distribution
by simulating a Gibbs sampler that iterates through the following steps: (i) update
θ; (ii) update λ; (iii) update γ, (iV) update βγ .
For the update to λ, we propose to update each λi in turn conditional on the
rest. That is, we update λi|λ−i,y, θ, σ2,β (i = 1, . . . , n), where λ−i indicates the λ
vector with the ith element removed.
The conditional distribution of λi does not have an explicit form; we thus resort
to the Metropolis-Hastings (MH) procedure with a proposal density q(λi, λ
∗
i ) that
generates moves from the current state λi to a new state λ
∗
i . The proposed updates
are then accepted with probabilities
α = min
{
1,
p(yi|λ∗i )p(λ∗i |λ−i, others)q(λi, λ∗i )
p(yi|λi)p(λi|λ−i, others)q(λi, λ∗i )
}
; (3.2)
otherwise the current state is retained. Similarly we need MH steps to draw θ.
3.3. Proportional Hazards Regression Model
The Cox proportional hazards model (Cox, 1972) assumes that the hazard function
consists of two parts: baseline hazard function and nonnegative function of covariates.
It is given by
h(t|x) = h0(t) exp(W )
where h0(t) is the baseline hazard function and W = x
′β where β is a vector of
regression coefficients. The Weibull model in the previous section is a special case
of Cox’s proportional hazard model with h0(t) = αt
α−1. Due to indetermination
of baseline hazard function, the proportional hazards (PH) model has adequately
adaptable for many applications (Kalbfleisch, 2002).
Kalbfleisch (1978) suggested the nonparametric Bayesian method for the PH
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model. We apply Bayesian variable selection approach to this model. In addition,
similar to Weibull regression model, we overcame the computation difficulties by
including a random residual component as
Wi = x
′
iβ + ²i where ²i ∼ N(0, σ2)
where X is the design matrix with ith column xi.
Let Ti be a independent random variable with conditional survival function
P (Ti ≥ ti|Wi,Λ) = exp{−Λ(ti) exp(Wi)} (i = 1, · · · , n).
Kalbfleisch (1978) suggested a Gamma process (GP) prior for the baseline cumulative
hazard function. He supposed that Λ ∼ GP(aΛ∗, a) where Λ∗ is the mean process
and a is a weight parameter about the mean (Ibrahim et al., 2001). Kalbfleisch(1978)
showed that if a ≈ 0, the likelihood is approximately proportional to the partial
likelihood and if a→∞, the limit of the likelihood is the same as the gamma process
is replaced by Λ∗. Since Λ(t) ∼ Gam(aΛ∗(t), a) for given t, the unconditional marginal
survival function is obtained by direct integration:
P (Ti ≥ t|W ) =
∫
exp (−r exp(W )) r
aΛ∗(t)−1
Γ(aΛ∗(t))a−aΛ∗(t)
exp(−ar)dr
=
(
a
a+ exp(W )
)aΛ∗
.
The joint survival function conditional on Λ is
P (T1 ≥ t1, · · · , Tn ≥ tn|W,Λ) = exp{−
∑
Λ(ti) exp(Wi)}.
Using a property of Gamma process, Kalbfleisch(1978) showed that the likelihood
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with some right censoring is
L(W|D) = exp{−∑ aBiΛ∗(ti)} n∏
1
{aλ∗(ti)Bi}νi
where
νi =
 0 if ti is right censored
1 if ti is a death time
,
Ai =
∑
l∈R(ti) exp(Wl) (j = 1, · · · , n), R(ti) is the set of individuals at risk at time
ti − 0 , Bi = − log{1 − exp(Wi)/(a + Ai)} and D = (n, t,ν) denotes the observed
data. The prior distributions are as follows:
[W|βγ ] ∼ MN(Xγβγ , σ2I)
[βγ ] ∼ MN(0, cσ2(Xγ ′Xγ)−1)
[γi] ∼ Bernoulli(pii)
[σ2] ∼ InverseGamma
(
a0,
b0
2
)
.
All conditional distributions are obtained in the next section.
3.3.1. Conditional Distributions in the Cox’s Proportional Model
The full conditional distribution of W is:
p(W|D,βγ , σ2) ∝ exp{−
∑
aBiΛ
∗(ti)}
n∏
1
{aλ∗(ti)Bi}νi
× exp
{
− 1
2σ2
(W −Xγβγ)′(W −Xγβγ)
}
In order to get the p(γ|W, σ2), we need to integrate out βγ and the approach
is similar to the Weibull regression situation.
The marginal distribution of γ given W and σ2 is
p(γ|W, σ2) ∝ p(W|γ, σ2)p(γ)
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∝ exp
{
− 1
2σ2
S(γ)
} n∏
i=1
pii
γi(1− pii)1−γi
where S(γ) = W′W − c
1 + c
W′Xγ(Xγ ′Xγ)−1Xγ ′W. Now rather than drawing γ
as a vector better to draw component wise from p(γi|λ, γj 6=i) which is
p(γi|W,γj 6=i, σ2) ∝ p(W|γ, σ2)p(γi)
∝ (1 + c)−qγ/2 exp
{
− 1
2σ2
S(γ)
}
pii
γi(1− pii)1−γi
p(γi = 1|W,γj 6=i, σ2) ∝ pii(1 + c)
−qγi1/2 exp
{
− 1
2σ2
S(γi
1)
}
p(γi = 0|W,γj 6=i, σ2) ∝ (1− pii)(1 + c)
−qγi0/2 exp
{
− 1
2σ2
S(γi
0))
}
where γi
1 = (γ1, · · · , γi = 1, · · · , γp) and γi0 = (γ1, · · · , γi = 0, · · · , γp),
p(γi = 1|W, γj 6=i, σ2) = 1
1 +
1− pii
pii
(1 + c)1/2 exp{−1
2
(S(γ0)− S(γ1))}
.
The conditional distribution of βγ is again
βγ |γ,W, σ2 ∼MN(VγXγ ′W,Vγ)
and the conditional distribution of σ2 is Inverse-gamma.
3.3.2. Bayes Factor Computation
In this non-conjugate complicated model, derivation of the marginal likelihoods in
explicit form is not possible. Chib and Jeliazkov (2001) overcame the problem of
calculation of the marginal likelihood by estimating it through Metropolis–Hastings
(M–H) output. We basically follow their two parameter blocks and multiple latent
variable blocks algorithm to get the Bayes Factors for Weibull model and modify it
for the Cox’s proportional hazard model.
For the Weibull model, let q(λ,λ′|D,βγ , θ) be the proposal density for the tran-
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sition from λ to λ′. And let
α(λ,λ′|D,βγ , θ) = min
{
1,
f(D|λ′, θ,γ)pi(λ′, θ)
f(D|λ, θ,γ)pi(λ, θ) ×
q(λ′,λ|D,θ,βγ)
q(λ,λ′|D,θ,βγ)
}
denote the acceptance probability for the move from λ to λ′. Using a basic marginal
likelihood identity
m(D) =
f(D|λ∗, θ∗)pi(λ∗, θ∗)
pi(λ∗, θ∗|D) for any λ
∗ and θ∗
and the following decomposition
pi(λ∗, θ∗|D) = pi(λ∗|D)pi(θ∗|D,λ∗),
the estimation of the marginal likelihood reduces to estimation of pi(λ∗|D) and
pi(θ∗|D,λ∗). Let
p(λ,λ∗|D, θ,βγ) = α(λ,λ∗|D, θ,βγ)q(λ,λ∗|D, θ,βγ)
be the subkernel of the M-H chain for λ conditioned on (θ,βγ) By a local reversibility
condition
p(λ,λ∗|D, θ,βγ)pi(λ|D, θ,βγ) = pi(λ∗|D, θ,βγ)p(λ∗,λ|D, θ,βγ)
and by integrating over ψ = (λ, θ,βγ) after multiplying both sides of the local
reversibility condition by pi(θ,βγ |D), we obtain finally
pi(λ∗|D) = E1
{
α(λ,λ∗|D, θ,βγ)q(λ,λ∗|D, θ,βγ)
}
E2
{
α(λ∗,λ|D, θ,βγ)
}
where E1 is expectation with respect to the distribution pi(λ, θ,βγ |D) and E2 is
expectation with respect to the distribution pi(θ,βγ |D,λ∗)× q(λ∗,λ|D, θ,βγ). The
numerator can be estimated by averaging the full run Monte Carlo samples and gthe
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denominator can be estimated by averaging the additional MCMC samples.
Since we cannot get the normalizing constant of pi(θ|D,λ∗), we need a similar
step to estimate it.
pˆi(θ∗|D,λ∗) = M
−1∑M
g=1 α(θ
(g), θ∗|D,λ∗)q(θ(g), θ∗|D,λ∗)
J−1
∑J
j=1 α(θ
∗, θ(j)|D,λ∗)
where θ(g) from pi(θ|D,λ∗) and θ(j) from q(θ∗, θ|D,λ∗) After that, we can get the
estimated logarithm of the marginal likelihood given by
log mˆ(D) = log f(D|λ∗, θ∗) + log pi(λ∗, θ∗)− {log pˆi(λ∗|D) + log pˆi(θ|D,λ∗)} .
For the Cox’s Proportional model, the estimation of the marginal likelihood is very
similar to the method for the Weibull model. The basic marginal likelihood identity
is
m(D) =
f(D|W∗)pi(W∗)
pi(W∗|D) .
An estimate of the marginal ordinate is similarly
pˆi(W∗|D) = M
−1∑M
g=1 α(W
(g),W∗|D,β(g)γ )q(W(g),W∗|D,β(g)γ )
J−1
∑J
j=1 α(W
∗,W(j)|D,β(j)γ )
where {W(g),β(g)γ } from the full run and β(j)γ from pi(βγ |D,W∗),W(j) from q(W∗,W|D,β(j)γ ).
Therefore, the logarithm marginal likelihood estimate is
log mˆ(D) = log f(D|W∗) + log pi(W∗)− log pˆi(W∗|D).
We can use these marginal likelihood calculations to obtain the Bayes factor to com-
pare two models. Kass and Raftery (1995) suggested that evidence against null model
H0 is very strong if twice the natural logarithm of the Bayes factor is greater than
10.
41
3.4. Examples
We apply the proposed methods to two data sets: Diffuse Large B-Cell Lymphoma
Data (Alizadeh et al., 2000) and Breast Carcinoma Data (Sørlie et al., 2001). In all
the examples we used MCMC method with a burn-in of 10,000 samples, after which
every 10th sample was retained in the next 100,000 samples.
3.4.1. DLBCL Data
We applied these methods for finding a set of responsible genes which explain the
survival function to a Diffuse Large B-cell lymphoma (DLBCL) data set (Alizadeh
et al., 2000). Diffuse large B-cell lymphoma (DLBCL) is one of subtypes of non-
Hodgkin’s lymphoma. But still patients with this disease had diverse responses to
current therapy. So Alizadeh et al. (2000) proposed that there should be some
different forms of DLBCL and discovered two distinct forms of DLBCL, activated
B-like DLBCL and GC–B like, using DNA microarray experiment and hierarchical
clustering. They showed that these two subgroups of DLBCL were differentiated
from each other by distinct gene expressions of hundreds of different genes and had
different survival time patterns.
There are 40 patients and expression level measurements for 4513 genes for each
patient. We consider the fixed binary covariate X0 as Xi0 = 1 if the ith sample
is Activated B-like and Xi0 = 0 if other case for i = 1, · · · , 40. Also we have the
expression level measurement for a set of genes, so Xij is the normalized log scale
measurement of the expression level of the jth gene for the ith sample, where i =
1, · · · , 40 and j = 1, · · · , 4513.
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3.4.1.1. Weibull Model
First we have used the parametric Weibull model. Using a two-sample t-test, 1000
genes are preselected and for the initial value of γ, the top five genes with largest
absolute t–value are used. The best subset found by the MCMC chains had only
4 genes included. We fixed this model and and reran the MCMC for additional
draws of {λ(g),β(g)γ , θ(g)}Gg=1. The survival function of Weibull model is S(t|λ, α) =
exp
(
− exp(λ)teθ
)
and using the MCMC samples we obtain its Monte Carlo estimates:
Sˆk(t|λ, α) = exp
(
− exp(λ¯k)teθ¯
)
, k = 1or 2 (3.3)
where k indicates class, λ¯k is the MCMC samle mean of λ in the class k and θ¯ is
the MCMC sample mean of θ. The 5th and 95th estimates of survival function use
the 5th MCMC sample percentile of λ and 95th estimates of survival function use
the 5th and 95th MCMC sample percentile of λ respectively instead of the MCMC
sample mean in equation 3.3. Also we compare this model with the no gene model
(model only with covariate X0) and the 2 log(Bayes Factor) comes out to be 33.98
which shows strong support for the selected model. Figure 4 shows two superimposed
survival curves based on Kaplan–Meier method (dash–dotted line) and Weibull model
(solid line) with 5th and 95th line (dotted line) for two groups, GC B–like (red) and
Activated B–like (blue). Comparing to the Kaplan–Meier curve, it is clear that the
fits are not satisfactory so we consider the semiparametric Cox’s proportional hazard
model to improve it.
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3.4.1.2. Cox’s Proportional Hazards Model
To develop the semiparametric model, we choose the baseline function Λ∗ as Weibull
distribution for the Gamma process on cumulative hazard function, that is, Λ∗(t) =
η0t
κ0 . We choose the hyperparameter as a = 10000. The estimates of hyperparame-
ters, η0 and κ0, are obtained using estimates of intercept and scale in Survreg function
(survReg(formula=Surv(y, censor) 1, dist=”weibull”) in S+. For our computational
convenience, 1000 genes are preselected by a two-sample t-test.
A 5 gene model comes out to be the best subset from the MCMC chain. We com-
pared this model with the best Weibull model using the Bayes factor and 2 log(Bayes Factor)
value is 14.81, which shows strong support for the semiparametric model. The survival
function in the Cox’s proportional hazard model is
S(t|W ) = P (T ≥ t|W ) =
(
a
a+ exp(W )
)aΛ∗
, (3.4)
and we exploited the posterior samples for this model to get the Monte Carlo estimate
of the function:
Sˆk(t|W ) = P (T ≥ t|W ) = 1
nk
∑
l∈Gk
(
a
a+ exp(W¯l)
)aΛ∗
for k = 1or 2.
where W¯l is the MCMC sample mean of Wl, Gk is the group of samples in class k and
nk is the size of Gk. The 5th and 95th survial function estimates use 5th percentile
and 95th percentil MCMC samples respectively instead of MCMC sample mean in
equation 3.4. The posterior estimates of survival curves (solid line) with 5th and
95th survival estimates(dotted line) are superimposed on the Kaplan-Meier estimates
(dash-dotted line) of survival functions (Figure 5). These plots show that this model
is a good fit to both of the subgroup of patients.
Rather than a single, parsimonious model, the biologists may be interested in
45
bigger families of genes to study relationships and functions. We presented some
selected genes based on the marginal frequencies in Table IX. Some of the identified
genes are already known to be biologically significant. Since MAPK10 (mitogen-
activated protein kinase 10) is connected to TNF(tumor necrosis factor)-a signaling
pathway(Decraene et al. 2002), its expression is directly related to the existence of
tumor. Rimokh et al. (1993) showed that FVT1 (follicular variant-translocation gene)
is highly expressed in some T-cell malignancies. WASIP(Wiskott-Aldrich syndrome
protein-interacting protein) is known to play a role in cortical actin assembly related
to lymphocyte function according to Ramesh et al. (1997).
A heatmap based on top two genes in Figure 6 shows that these two gene ex-
pression patterns are related to survival time and are distinct between two groups.
That is, GC B-like and Activated B-like have different gene expressions and survival
times.
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Table IX. Responsible Genes Found for Estimating the Survival Function DLBCL
Data
Freq Clone ID Gene Symbol Gene Name
1014 1355868
910 290230 ICSBP1 interferon consensus sequence binding protein 1
405 814260 FVT1 follicular lymphoma variant translocation 1
289 1353111 MDS019 phorbolin-like protein MDS019
180 683069 EST
156 1340233 FGD3 ”FGD1 family, member 3”
156 23173 MAPK10 mitogen-activated protein kinase 10
154 814601
132 1335070 ESTs
132 1303587
124 1337701 WASPIP Wiskott-Aldrich syndrome protein interacting protein
121 824198 (FUBP1) Homo sapiens far upstream element (FUSE)
binding protein 1
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3.4.2. Breast Carcinoma Data Set
Breast carcinoma data was described in Sørlie et al. (2001). They found some novel
subclasses of breast carcinoma based on gene expression patterns and proved robust-
ness of subclasses using separate gene sets. A part of patients with the same therapy
had different overall and relapse-free survival patterns. We use overall survival times
of 76 samples each with 3097 gene expressions. There is also additional subgroup
information: Basal-like, ERBB2+, Normal Breast-like, Luminal Subtype A, B, or
C. We only consider the binary covariate X0 as: Xi0 = 1 if ith sample is Luminal
subtype A, B, or C and 0 otherwise. We can extend it to a muti-category case by
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adding other covariates in the model.
3.4.2.1. Weibull Model
The best subset found by the MCMC chain had only 6 genes included. The 2 log (Bayes factor)
of this model compared to the no-gene model was calculated to be 33.46. The pos-
terior survival curve has been plotted in Figure 7, which again shows there is still
room to improve the fitness of the model. Figure 7 shows two superimposed survival
curves based on Kaplan-Meier method (dash-dotted line) and Weibull model (solid
line) with 5th and 95th line (dotted line) for two groups, Luminal subtyes A,B, or C
(red) and others (blue). Comparing to the Kaplan-Meier curve, it is clear that the
fits are not satisfactory so we consider the semiparametric Cox’s proportional hazard
model to improve it.
3.4.2.2. Cox’s Proportional Model
We perform our analysis with a semiparametric model using the previous data. A
5 gene model becomes the best subset. The 2 log Bayes factor value compared to
the best Weibull model is 19.38. The posterior survival curves based on this model
is given in Figure 8. Figure 8 shows two superimposed survival curves based on
Kaplan-Meier method (dash-dotted line) and Cox’s proportional hazard model (solid
line) with 5th and 95th line (dotted line) for two groups, Luminal subtyes A,B, or C
(red) and others (blue).
We presented some of the selected genes based on the marginal frequencies
in Table X. Some of the genes are already shown to significant as Theillet et al.
(1993) showed that PLAT(plasminogen activator) could be amplified in breast can-
cer. CYP1B1(cytochrome p450-1B1) plays a possibly critical role in the cause of
breast cancer (Zheng et al. 2000).
50
A heatmap of these genes is provided in Figure 9 and there are some patterns:
selected genes are overexpressed in group1 and survival times are related to the level
of gene expressions. Three genes are selected through our proposed method. Two
survival groups show different patterns and this finding corresponds to the pattern of
actual gene expressions.
3.5. Discussion
We have proposed Bayesian models for variable selection in the survival regression
models with specific application to analyze microarray data. We obtain nice estimate
of the survival curves with an extremely small number of genes. On the other hand,
bigger families of genes can be useful to biologists to study the relationship and
functions. Information on the size of models for prediction can be easily included
in our Bayesian search of good models. The method has flexbility of allowing the
location of larger sets of genes, via the inspection of the best visited models or the
marginal probabilities of single genes, as we have illustrated.
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Table X. Responsible Genes Found for Estimating the Survival Function for Breast
Carcinoma Data
Freq. Clone ID Gene Symbol Gene Description
3826 340826 Homo sapiens cDNA FLJ12749 fis,
clone NT2RP2001149
1225 772890 Homo sapiens mRNA; cDNA DKFZp434N2412
1203 272018 ESTs, Weakly similar to AF126743 ...
1028 772304 SLC25A5 solute carrier family 25
593 813841 PLAT plasminogen activator, tissue
573 745402 PRO2975 hypothetical protein PRO2975
396 40299 GDF10 growth differentiation factor 10
395 79045 CTL1 transporter-like protein
365 950578 NDUFA5 NADH dehydrogenase 1 alpha subcomplex, 5
263 782760 CYP1B1 cytochrome P450, subfamily I, polypeptide 1
229 768299 BRF1 butyrate response factor 1 (EGF-response factor 1)
198 951125 PECI peroxisomal D3,D2-enoyl-CoA isomerase
185 131653 MRPS12 mitochondrial ribosomal protein S12
151 771323 PLOD procollagen-lysine, 2-oxoglutarate 5-dioxygenase
143 755599 IFITM1 interferon induced transmembrane protein 1 (9-27)
132 214448 RNF10 ring finger protein 10
113 83610 FLJ22378 hypothetical protein FLJ22378
111 134476 SYBL1 synaptobrevin-like 1
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CHAPTER IV
CURVE CLUSTERING IN THE MICROARRAY DATA
4.1. Introduction
After a novel technology, microarray, was introduced, many statistical issues have
been raising including clustering. When gene expressions are observed by time or
temperature, we want to cluster these gene expressions. In the setting of time–course
gene expression, clustering methods can be divided into two categories: non–model–
based methods and model–based methods. Non–model–based methods are such as hi-
erarchical clustering (Eisen et al.,1998), clustering using correlation(Chu et al.,1999),
self–organizing maps (Tamayo et al.,1999). Mixture-effects model with B–splines
(Luan et al.,2003) and hidden Markov model (Schliep et al.,2003) are considered
methods in model–based methods. We are motivated by Wakefield et al.(2003) who
modeled the trajectory as a function of time and gene specific parameters and clus-
tered these curves based on gene specific parameter using a reversible jump MCMC.
Wakefield et al.(2003) used a first–order random walk model for gene–based parame-
ters in a sporulation data (Chu et al., 1999) and a mixture of periodic function model
for the cell–cycle data (Spellman et al. 1998).
In this chapter, we propose a mixture of Dirichlet processes model using discrete
wavelet transform for curve clustering as a fully Bayesian approach. In order to char-
acterize these time–course gene expressions, we consider them as trajectory functions
of time and gene specific parameters and obtain their wavelet coefficients by discrete
wavelet transform. We then build cluster curves based using a mixture of Dirichlet
processes prior. Each iteration of MCMC algorithm generates the cluster structure
of these coefficients as a by–product (Escobar et al., 1998). In addition, when mi-
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croarray have missing data points, we estimate their missing data points in MCMC
sampling using their conditional distribution. Subsequently, the proposed models are
applied to two yeast cell cycle microarray data sets: Cho et al. (1998) and Spellman
et al. (1998).
4.2. Bayesian Hierarchical Model
4.2.1. Mixture of Dirichlet Processes
Ferguson(1973) defined a Dirichlet process (DP) for a Bayesian nonparametrci ap-
proach as follows: Let µ be a finite non-null measure on (X ,B) where X is a space
and B is a σ-field of subsets. If for any k ∈ {1, 2, · · · , } and any measurable partition
(B1, · · · , Bk) of X ,
(P (B1), · · · , P (Bk)) ∼ Dirichlet(µ(B1), · · · , µ(Bk))
then a stochastic process P is defined as a Dirichlet process DP(µ) on (X ,B) with
parameter µ. Especially, when µ = αG0 with G0 is distribution, E(P (B)) = G0(B)
and V ar(P (B)) =
G0(B)(1−G0(B))
α + 1
for any B ∈ B. In this case,G0 is called the
base measure, α is called the precision parameter, and DP is denoted by DP(α,G0)
to acknowledge the dependence µ through α and G0. Escobar and West(1998) ex-
plored Dirichlet process DP(α,G0) in order to model the “uncertainty” of the prior
distribution, while referring to G0 as the “location” distribution of Dirichlet pro-
cess prior. We are interested in the following property of Dirichlet process: given a
set of β = {β1, · · · , βI} from a random distribution G following a Dirichlet process
DP(α,G0), the conditional distribution
βi|β−i ∼
α
α+ I − 1G0 +
1
α+ I − 1
∑
j 6=i
δ(βi|βj), β−i = {βj ∈ β : j 6= i}
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follows a mixture of Dirichlet process. Formal definition of a mixture of Dirichlet
Process can be found in Antoniak(1974).
An important property in the MDP model is that with positive probability some
of the βi have the same value because of the discretness of random measure of MDP
(MacEachern et al., 1998) and clustered property of data. Escobar and West(1998)
point out the Polya urn representation for the joint posterior distribution of [βi|·]
[dβi|Y,β−i, ·] ∝
I∏
i=1
f(Yi|βi, ·)
αG0(dβi|σ2,V) +
∑
k 6=i δ(βi|βk)
α + i− 1
4.2.2. Wavelet Regression
For the ith gene, Yit is the normalized log-ratio of mRNA gene expression level relative
to the gene expression of the reference cell at time t, where i ∈ {1, · · · , I} and t ∈
{1, · · · , T} ; I is the number of genes and T is total number of equally spaced time
points. We assume that Yi = (Yi, · · · , YiT ) is the the vector of observations of the ith
trajectory function with additive white noise
Yit = f(θi, t) + ²it, ²it ∼ N(0, σ2)
where f(θi, t) is a trajectory function of a gene-specific set of parameter,θi and time
t (Wakefield et al., 2003). The trajectory function can be represented in terms of
shifted and dilated scale functions {ψ(t)} and wavelet functions {φ(t)} as follows:
f(t) ≈
2j0−1∑
k=0
skφj0k(t) +
J∑
j=j0
2j−1∑
k=0
wjkψjk(t)
where J = log2 T , j ≥ 0 ≥ 0, uk =< f, φj0k > and wjk =< f, ψjk > (Daubechies,
1992) or equivalently we may write the model as
f = Xβ
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where β is the wavelet representation of the true function f and X′ is the T ×
T orthogonal wavelet transformation. In this chapter, we only assume orthogonal
wavelet bases and avoid more general representations for questions of stability and
bias introduced in estimation.
4.2.3. Generic Wavelet Based Dirichlet Process Model
The proposed method looks for relevant clusters in the observed curves by the poste-
rior sampling of the wavelet coefficients in Dirichlet process mixtures DP(α,G0).
The prior of covariance Σ is modified as in an example of normal structure in
Escobar and West(1998) and assume the following hierarchical structure :
[Yi|βi, σ2] ∼ N(Xβi, σ2I),
[βi|µ,Σ] ∼ DP
(
α,MN(µ, σ2Σ)
)
,
[σ2] ∼ IG
(
ν1
2
,
ν2
2
)
,
[α] ∼ G(a, b).
Σ = diag ({vjk} , 0 ≤ k ≤ 2j−1, j0 ≤ j ≤ J)and is intended for shrinkage with
[vjk] ∼ IG
(
sjk
2
,
rjk
2
)
, 0 ≤ k ≤ 2j−1, j0 ≤ j ≤ J
where rj· and sj· are specified levelwise to maintain a mean of roughly n2−cj for some
constant c. Here, the constant c models the decay in the average size of wavelet
coefficients and, thus, the mean of the inverse gamma prior, E(vjk) = sjk/(rjk − 2),
rjk > 2 is specified to match this decay. For all k, fixing rj· = c+2, we get sj· = cn2−cj.
The posterior distributions are as follows:
[βi|Y, {βk, k 6= i}, σ2,Σ] ∝ exp
{
−σ
2
2
I∑
i=1
(Yi −Xβi)′(Yi −Xβi))
}
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×
 α
α + I − 1MN(µ, σ
2Σ) +
1
α + I − 1
∑
j 6=i
δ(βi|βj)j

∝ q0MN(µi, σ2V) +
∑
j 6=i
qjδ(βi|βj)
where V = (Σ−1 + I)−1 , µi = V (Σ−1µ+X′Yi) and the weights qj are defined as
q0 ∝ αφ(Yi|Xµ, σ2(I +X′ΣX))
qk ∝ φ(Yi|Xβk, σ2I)
subject to
∑
j 6=i qj = 1, where φ(y|θ,Υ) is the multinormal density function of mean
θ and covariance Υ. Since the conditional probability of sampling a new β is propor-
tional to q0, if it is small relative to the sum of other qj’s, the number of distinct βi’s is
also small and samples of β’s change much. Let superscript * denote distinct values.
Escobar and West (1998) used a “remixing algorithm” in order to avoid this problem
by resampling β∗j at each iteration, and to, additionally, improve the convergence.
[β∗j |Y, σ2,Σ] ∝MN(µ∗j , σ2V∗j ) for each j = 1, · · · , I∗
where V ∗j = (Σ
−1 + |J(j)|I)−1 , µ∗j = V ∗j (Σ−1µ +
∑
j∈J(j)
X′Yj) and J(j) is the index
set of j th cluster
Since
[
σ2,β|Y
]
∝
(
1
2σ2
)I·T/2
exp
{
− 1
2σ2
I∑
i=1
(Yi −Xβi)′(Yi −Xβi)
}
×
(
1
2σ2
)I·T/2
exp
{
− 1
2σ2
I∑
i=1
(βi − µ)′Σ−1(βi − µ)
}
×IG
(
ν1
2
,
ν2
2
)
,
the full conditional distribution of σ2 after integrating out β is
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[
σ2|·
]
∼ IG
(
ν1 +N
2
,
S
2
)
where S =
∑I
i=1 (µ
′Σ−1µ+Y′iYi − µ′iV−1µi) + ν2 and N = I · T .
In addition, with (βi|Σ, σ2) ∼ N(µ, σ2Σ), the posterior distribution of scaling
parameters vjk are drawn as
(vjk|βi, σ2) ∼ IG
(
s∗jk
2
,
r∗jk
2
)
where s∗jk = I + sjk and r
∗
jk = (σ
2)−1
∑I
i=1(βik − uk)2 + rjk.
The precision parameter α in the Dirichlet process plays an important role in
determining the number of clusters. Assuming a continuous prior density for p(α),
Escobar and West(1995) provided a distribution of number of components through
Antoniak(1974)’s results
p(I∗|α, I) = cI(I∗)I!αI∗Γ(α)/Γ(α+ I), I∗ = 1, · · · , I.
where cI = p(I
∗|α = 1, I) and Γ(·, ·) is the Gamma function. According to the
relationship between the Gamma function and the Beta function,
Γ(α)
Γ(α + I)
=
(α + I)β(α+ 1, I)
αΓ(I)
,
where β(·, ·) is the Beta function, the p(α|I∗) can be written as follows:
p(α|I∗) ∝ p(I∗|α)p(α)
∝ p(α)αI∗−1(α + I)
∫ 1
0
ηα(1− η)I−1dη
and it can be considered as the marginal distribution (of α) from a joint distribution
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for α and a latent variable η such that
p(α, η|I∗) ∝ p(α)αI∗−1(α+ I)ηα(1− η)I−1.
Therefore choosing p(α) to be G(a, b), leads to
p(α|I∗, η) ∼ piηG(a+ I∗, b− log(η)) + (1− piη)G(a+ I∗ − 1, b− log(η)),
where
piη
1− piη =
a+ I∗ − 1
I(b− log(η)) .
Next, η is updated as
p(η|α, I∗) ∝ ηα(1− η)I−1 = Beta(α+ 1, I).
4.3. Missing Data Case
The gene expressions Yi = (yi1, yi2, . . . , yiT ) are recorded expression levels at successive
times points (1, 2, . . . , T ). In case, the expressions at some time points are missing,
we proceed as follows.
Recall that for the ith curve
(Yi|µ,Σ, σ2) ∼ N(Xµ, σ2(I +XΣX ′)), ∀i = 1 . . . I
Stratify Y ′i as (Y
′
i(1), Y
′
i(2)) where Yi(1) is a vector of ri × 1 observations and Yi(2)
is a vector of (T − ri)× 1 missing data. Write, Λ = (I +XΣX ′), then corresponding
to the split in the observed vector, create partitions in
Xµ =
 (Xµi)1
(Xµi)2
 and Λ =
 Λi11 Λi21
Λi21 Λi22

then the missing data is drawn conditional on the observed time points of the ith
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curve as
(Yi(2)|Yi(1), ·) ∼ N((Xµi)2 + Λi21Λ−1i11(Yi(1) − (Xµi)1), σ2(Λi22 − Λi21Λ−1i11Λi12))
This extra sampling step is iterated with the Gibbs sampler in the previous section.
4.4. Application to cDNA Microarray Data
We apply our proposed hierarchical model to two yeast cell cycle data and check
the model adequacy using the Bayesian Information Criterion, BIC, introduced by
Schwarz (1978),
BIC = −2 · logLˆ+ log(n) · p
where Lˆ is the maximized likelihood and p is the number of parameter in the model. If
the ratio of BIC of two models is considered, it is known to provide an approximation
of 2 log(Bayes Factor) for sufficiently large sample n (Schwarz, 1978).
4.4.1. The Yeast Cell Cycle Data I
Cho et al. (1998) obtained time courses of more than 6000 genes over nearly two full
cell cycles (17 time points) and found that 416 among them have periodic-fluctuations
in the gene expression due to their cell cycle-dependency. Genes were categorized into
five-phases, early G1, late G1, S, G2 and M by their different peak points. Cho et al.
(1998) identified that 33 of 416 genes have peak points in two different phases. So
we used 384 genes for application to our proposed model and compare our clustering
results with their identified phases. The data was log transformed and standardized
across the cell cycle.
We used the last 16 time points for the computational convenience in the Discrete
Wavelet Transform. We compared our clustering result with Cho et al. (1998) using
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the adjusted Rand index(Hubert and Arabie, 1985), which evaluates the measure of
agreement of two different partitions of one data set and overcomes the problem of
non-constant expected value of Rand index (Rand, 1971), the fraction of agreement.
Especially Milligan and Cooper (1986) recommended the adjusted Rand index as an
external measure after extensive comparisons. If the cluster is random, the expected
value of adjusted Rand index is 0. Its maximum value is 1 which indicates the perfect
match between the clustering result and the external standard. The more details on
the adjusted Rand index is referred to Yeung and Ruzzo (2000).
Table XI shows the comparison of two partitions. The adjusted Rand index based
on Table XI is 0.4563 and we can see how sharply they are clustered. BIC of the model
(=2294.8) is much lower than the BIC of Cho et al.’s clustering (=3659.7). Cho et
al. (1998) classified these genes based on their peak time but our proposed model is
based on the trajectory pattern. So it may be the reason of relative low adjusted Rand
index and the lower BIC of our model supports that our proposed model clusters
these curves sharply. In addition, the distribution of I∗ do not change much in
the same analysis with various priors of α; Gamma(0.0001, 0.0001), Gamma(1, 1),
Gamma(2, 1), and so on.
Figure 10 shows five curve clusters of 384 genes by Cho et al. (1998) and Figure
11 shows those generated by our proposed model.Compared with Figure 10, our model
shows clearer classification schemes (C1−D3, C2−D1, C3−D5, C4−D2, C5−D4).
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Table XI. Two Partitions of Yeast Cell Cycle Data (C: Clusters by Cho et al. (1998)
and D: Clusters by Our Proposed Model)
Class C1 C2 C4 C5 C3 Sums
D1 40 14 0 0 1 55
D2 7 117 0 0 38 162
D5 0 1 41 3 35 80
D4 3 0 7 37 1 48
D3 17 3 4 15 0 39
Sums 67 135 52 55 75
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4.4.2. The Yeast Cell Cycle Data II
Spellman et al. (1998) carried out DNA microarray experiments in order to make a
new comprehensive list of yeast genes whose gene transcription levels have periodical
patterns within the cell cycle. They generated three microarray data sets from the
yeast cell cultures synchronized by different methods: α factor arrest, elutriation and
arrest of a cdc15 temperature-sensitive mutant. Samples in the first data were taken
every 7 minitures from 0 minture to 140 minute, but α factor was removed after
120 minutes. So the number of time points is 18. We pre–selected 400 genes with
large variance over time. We transform the data using the Box–Cox family of power
transformation, with λ = 0.1, for the normality.
Yλ =

Y λ − 1
λ
, if λ 6= 0
log(Y ), if λ = 0
We consider the missing data points and at every 5th iteration, the missing points
are estimated to improve the speed of MCMC. Figure 12 shows that the estimated
data does not show difference from the original data.
We obtained six clusters by our proposed model and the BIC of this model is
2501.473 Figure 13 shows the well clustered membership.
4.5. Discussion
We have proposed a Bayesian model for curve clustering and identified genes which
has similar trajectory function over time. We have used a Bayesian hierarchical
model and Dirichlet process prior of discrete wavelet coefficients. And by product of
it, we obtained clustering result in each iteration and we used the marginal posterior
mode of the clustering membership of genes. Additionally, we easily estimated the
missing data using the conditional distribution. Finally, we finish this chapter by
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pointing out two potential shortcomings of the proposed procedure. First, it should
be remarkedthat the procedure of this chapter can not be applied to classification
problem, known the number of clusters. Second, if the time is not equally spaced,
we could not use the discrete wavelet transform directly, however, the latter can be
handled by a lifting technique.
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Fig. 10. Five Clusters of Expression Time Courses in Yeast Data (Cho et al., 1998)
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Fig. 11. Five Clusters of Expression Time Courses by Our Proposed Model in Yeast
Data (Cho et al., 1998)
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70
2 4 6 8 10 12
−1
0
1
2
2
9
4
2 4 6 8 10 12
−1
0
1
4
0
2 4 6 8 10 12
−1
0
1
2
2
3
2 4 6 8 10 12
−1
0
1
1
6
2 4 6 8 10 12
−1
0
1
1
6
2 4 6 8 10 12
−1
0
1
2
1
1
Fig. 13. Six Clusters of Expression Time Courses by Our Proposed Model in Yeast
Data (Spellman et al., 1998)
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CHAPTER V
SUMMARY AND DISCUSSION
The objective of this research is to propose new Bayesian approaches in variable
selection and clustering for application to the cDNAmicroarray data. At first, we have
introduced some background of microarray and reviewed some related literatures. In
Chapter II, we have proposed a Bayesian hierarchical model to identify important
genes using expression level data to characterize binary categories of samples. We
have used a hierarchical probit model and MCMC based stochastic search technique
to obtain the posterior samples. We have mainly used Gibbs algorithm in this paper
but in future we will investigate the more adaptive MH algorithm (or a mixture of
two) to speed up our computation.
Here we have fixed the pi value but we can extend our model assuming pi is an
unknown model parameter. Assigning a conjugate beta distribution prior on pi, the
extension is straightforward.
Though we have assumed the genes are independent but in our framework we
can very easy extend it for dependent cases. For example: suppose if the event that
the ith gene is expressed increases the chance that jth gene will be expressed too. In
our frame work we can include it through the prior distribution of γ. Rather than
taking all the γi are independently distributed we can use a Markov model whose
transition matrices will be defined as p(γj = 1|γi = 1) or so. This type of problems
will be handled in future research.
We have considered binary data. Extension to more than two categories can be
found in Albert and Chib (1993) and development of a variable selection model in
that setup is in Sha (2002).
In Chapter III, we have proposed Bayesian models for variable selection in the
72
Weibull survival regression model and Cox’s proportional hazard model with specific
application to analyze microarray data. We have obtained nice estimates of the
survival curves with an extremely small number of genes. On the other hand, bigger
families of genes can be useful to biologists in studying the relationships and functions.
Information on the size of models for prediction can be easily included in our Bayesian
search of good models. The method has the flexibility of allowing the location of larger
sets of genes, via the inspection of the best visited models or the marginal probabilities
of single genes, as we have illustrated.
In Chapter IV, we have proposed a new model-based approach for curve cluster-
ing. We have proposed a mixture of Dirichlet process model using discrete wavelet
transform for a curve clustering as a fully Bayesian approach. In order to charac-
terize these time-course gene expresssions, we have considered them as trajectory
functions of time and gene-specific parameters and obtained their wavelet coefficients
by discrete wavelet transform. Then we have clustered curves based on them useing
a mixture of Dirichlet process. Each iteration of an MCMC algorithm generates the
cluster structure of these coefficients as a by–product (Escobar et al., 1998). We have
used a marginal posterior mode of their cluster memberships.
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APPENDIX A
DERIVATION OF THE COMPLETE CONDITIONAL DISTRIBUTIONS
Z|βγ ∼ N(Xγβγ, 1)
βγ ∼ N(0, c(X ′γXγ)−1)
p(Z|βγ)p(βγ) ∝ exp{−1
2
(Z −Xγβγ)′(Z −Xγβγ)}
× 1
cqγ/2|X ′γXγ|−1/2
exp{− 1
2c
β′γ(X
′
γXγ)βγ}
where qγ =
∑
γi.
Since
p(Z|βγ)p(βγ) ∝ 1
cqγ/2|X ′γXγ|−1/2
exp{−1
2
(1 + c−1)β′γ(X
′
γXγ)βγ + Z
′Xγβγ} exp{−1
2
Z ′Z}
= exp{−1
2
β′γV
−1
γ βγ + β
′
0V
−1
γ βγ −
1
2
β′0V
−1
γ β0}
1
cqγ/2|X ′γXγ|−1/2
exp{−1
2
Z ′Z}
where
Vγ = (1 + c
−1)−1(X ′γXγ)
−1,
β0 = VγX
′
γZ = (1 + c
−1)−1(X ′γXγ)
−1X ′γZ,
and
|Vγ|1/2
(cqγ |X ′γXγ|)1/2
=
(
1
1 + c
)qγ/2
,
p(Z|γ) ∝
∫
p(Z|βγ)p(βγ)dβγ
∝
(
1
1 + c
)qγ/2
exp{−1
2
S(γ)}.
where S(γ) = Z ′Z − c
1 + c
Z ′Xγ(X ′γXγ)
−1X ′γZ.
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So
p(γ|Z) ∝ p(Z|γ)p(γ)
∝ (1 + c)−qγ/2 exp(−1
2
S(γ)).
Since
p(γi|Z, γj 6=i) ∝ p(Z|γ)p(γi)
∝ piγii (1− pii)1−γi(1 + c)−qγ/2 exp(−
1
2
S(γ)),
p(γi = 1|Z, γj 6=i) ∝ pii(1 + c)−qγ1/2 exp(−1
2
S(γ1))
p(γi = 0|Z, γj 6=i) ∝ (1− pii)(1 + c)−qγ0/2 exp(−1
2
S(γ0))
where γ1 = (γ1, · · · , γi = 1, · · · , γp) and γ0 = (γ1, · · · , γi = 0, · · · , γp),
p(γi = 1|Z, γj 6=i) = 1
1 +
1− pii
pii
(1 + c)1/2 exp{−1
2
(S(γ0)− S(γ1))}
Since p(βγ|Z) ∝ p(Z|βγ)p(βγ),
p(βγ|z) ∝ exp{−1
2
(βγ − β0)′V −1γ (βγ − β0)}.
So the posterior distribution of βγ is
βγ|Z ∼ N(β0, Vγ)
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